IGFBP3 and neoplasm: Ibanez de Caceres and colleagues reported that a loss of insulin-like growth factor binding protein-3 (IGFBP-3) expression, mediated by promoter hypermethylation, resulted in a reduction of tumor cell sensitivity to cisplatin in NSCLC.